Surrozen Inc (SRZN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$22.76+0.98%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Surrozen is advancing novel antibody therapies for cancer and autoimmune diseases. It has shown some earnings beats, like in August 2025 and November 2025. The company has stable management and a market cap near $290 million, suggesting room for growth if trials succeed.
Surrozen is loss-making with negative EPS around -$1.29 next quarter and -$3.7 for fiscal 2026. It recently missed earnings twice and faces a 32.6% stock drop. The termination of a key collaboration and officer departures raise concerns about execution.
The market is selling off sharply with a 32.6% drawdown from highs, reflecting skepticism on Surrozen's ability to turn profitable soon. There is no clear consensus revenue growth or fair value, indicating uncertainty. Our view is cautious given the weak earnings and recent negative news.
Breaks if: EPS remains below -1.0 next 4 quarters
Breaks if: Failure to achieve key clinical or regulatory milestones in 12 months
Breaks if: Revenue declines below $3.5M FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth thesis. SRZN is currently navigating a challenging landscape with mixed recent results and elevated risk, while also focusing on advancing its drug pipeline.
The market appears to have priced in a premium compared to peers, reflecting a significant expectations gap. However, the valuation is considered unjustified given the company's loss-making status and recent performance issues.
Fundamentals are likely to remain under pressure due to ongoing losses and a high probability of missing earnings in the near term. Management is focused on key priorities, but recent financial performance has been neutral and below industry standards.
The long-term thesis hinges on the success of SRZN's drug development pipeline and the performance of sector bellwethers. If these companies continue to perform well, it could provide a favorable backdrop for SRZN.
Over the next 1 to 3 years, SRZN's trajectory will depend on its ability to execute on its development plans and navigate sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.